Impact of competition on reimbursement decisions for cancer drugs in China: an observational study.

The differences between reimbursed and non-reimbursed indications did not reach statistical significance for median (interquartile range) gains in OS (2.8 [2.1–5.0]) vs 2.6 [1.9–5.1]; p = 0.58) and PFS (4.3 [2.9–5.8] vs 2.7 [1.6–4.7]; p = 0.10).

also in 111,027 other papers